The standard regimen involves: Loading doses without neurological involvement : 1 mg intramuscularly three times a week for 2 weeks [3] [8] Loading doses with neurological involvement : 1 mg intramuscularly on alternate days until no further improvement [3] [8] Maintenance therapy : 1 mg every 23 months for life in cases of pernicious anaemia or irreversible malabsorption (every 2 months if neurological involvement) [3] [8] This aggressive approach aims to prevent irreversible neurological damage, though recovery of established neuropathy may be incomplete, particularly if treatment is delayed
The evidence reviewed on this page does not support claims of efficacy for any human disease or condition
Hi, Im Rachel Stahl
From day 1 of the experiment to day 5 the escape latency was found to remarkably decrease, however, escape latency in the APP/PS1 mice was higher than that of the wild type mice
Despite initial enthusiasm for cuproptosis as a novel pathogenetic mechanism [27,51,54] , the molecular and metabolic complexities underlying copper-dependent hepatocellular injury in Wilson disease remain unresolved, especially since the role of ROS and reactive copper intermediates was not originally included in the cuproptosis framework [51,54]
Consult your provider before use